Menu

Thomas LEFEBVRE

Paris

En résumé

Scientist PhD drug discovery-oriented, specialized in GPCRs and ion channels. Topics of studies: screening, GPCRs (desorphanization, signaling and dimerization), ion channels (pharmacology and physiology), nervous system diseases, stereotactic surgery and animal behavior. Significant experience in therapeutic target evaluation and as a drug discovery team leader.

Skills: Project Management - Assay Development - Preclinical Pharmacology

- Cell-based assays: GPCR signaling, cytotoxicity assays, FACS, siRNA
- Cell culture: tissue slices, microexplants, primary neuronal cells, recombinant mammalian cells
- Molecular biology: RNA extraction, Q-RT-PCR, PCR, subcloning, gel agarose electrophoresis
- Stereotactic surgery: lesioning and cannulation
- Small molecules screening
- Histology: immunofluorescence and image analysis by confocal microscopy
- Patch-clamp electrophysiology: whole-cell recordings, neuronal activity

Mes compétences :
Project management
Cell biology
Animal behavior
Electrophysiology
High throughput screening
in vitro pharmacology
GPCRs
Drug discovery
Cell based assays

Entreprises

  • Actelion

    Paris maintenant
  • Inserm

    PARIS 13 maintenant
  • Idorsia Pharmaceuticals Ltd - Principal Scientific Associate

    2017 - maintenant
  • Actelion - Principal Scientific Associate

    Paris 2016 - 2017
  • Actelion - Research Associate

    Paris 2014 - 2015
  • Actelion Pharmaceuticals Ltd. - Scientist - Project Leader

    2010 - 2012 Drug-discovery in CNS Biology.

    - Cell culture: recombinant mammalian cell lines (transfection, clone selection and validation).
    - Cell-based assays linked to GPCRs signaling: calcium measurement (FlipR), cAMP release (HTRF and luciferase reporter assays), Beta-arrestin recruitment, label free, dimerisation, cell proliferation and cytotoxicity assays.
    - FACS and Q-RT-PCR to validate receptor expression.
    - SiRNA-mediated gene silencing.
    - High Throughput Screening
  • Synaging SAS - Scientist - Project Leader

    2010 - 2014 - Drug-discovery program: deorphanisation of a GPCR and validation of the target in CNS diseases. Assay development & screening. Hits actually validated in a secondary phenotypic screen.
    - Preclinical pharmacology: development of in vitro and in vivo models of CNS diseases, compound profiling, proof of concept mechanism.
    - CRO activities: from protocol setup with clients to sample tracking, data management, statistical and reporting activities.

Formations

Réseau

Annuaire des membres :